

AUSTRALIAN PRODUCT INFORMATION –

APO-ONDANSETRON ODT (ONDANSETRON)

1 NAME OF THE MEDICINE

Ondansetron

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each orally disintegrating tablet contains 4 mg or 8 mg ondansetron, as the active ingredient.

Excipients with known effect

Aspartame (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE);

For the full list of excipients, see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

4 mg Orally Disintegrating Tablets:

White, round shaped, flat faced bevelled edge tablets debossed with 'P' on one side and '92' on the other side.

8 mg Orally Disintegrating Tablets:

White, round shaped, flat faced bevelled edge tablets debossed with 'P' on one side and '91' on the other side.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

4.2 DOSE AND METHOD OF ADMINISTRATION

Ondansetron tablets, injections and suppositories are unavailable in this brand, however these dosage forms are available in other brands. Dosage, pharmacokinetic, clinical trial and adverse effect information obtained using ondansetron tablet, injection and/or suppository formulations have been retained in the relevant sections for prescriber information.

The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The dose of ondansetron should be flexible in the range of 8 to 32 mg a day and selected as shown below. The lowest effective dose should be used.

The ondansetron orally disintegrating tablet is administered by placing on top of the tongue where it dissolves within seconds, and is swallowed.

Use in Adults

Emetogenic chemotherapy and radiotherapy

For the control of chemotherapy or radiotherapy induced emesis or nausea in adults, two oral doses of 8 mg each at **12 hourly intervals** may be given, the first dose being administered 2 hours prior to chemotherapy or radiotherapy.

To protect against delayed emesis after the first 24 hours, ondansetron should be continued orally at a dosage of 8 mg **twice daily** for up to 5 days after a course of treatment.

Highly emetogenic chemotherapy

A single oral dose of up to 24 mg ondansetron taken with oral dexamethasone 12 mg, 1 to 2 hours before commencing chemotherapy.

Initial treatment may be followed by oral ondansetron 8 mg 12-hourly for up to 5 days to protect against delayed emesis.

Use in Paediatrics

Emetogenic chemotherapy and radiotherapy

Experience is currently limited but ondansetron was effective and well tolerated in children over the age of 4 years, when given intravenously at a dose of 5 mg/m² over 15 minutes, immediately before chemotherapy, followed by oral therapy at doses of 4 mg twice daily for up to 5 days. The dose of 5 mg/m² is based on limited data.

Use in Elderly Patients

Emetogenic chemotherapy and radiotherapy

Efficacy and tolerance in patients aged over 65 years was similar to that seen in younger adults indicating no need to alter dosage or route of administration in the elderly.

Chemotherapy-Induced Nausea and Vomiting (CINV) and Radiotherapy-Induced Nausea and Vomiting (RINV) in Elderly Patients

Ondansetron is well tolerated by patients over 65 years of age.

No alteration of oral dose or frequency of administration is required

Patients with Renal Impairment

No alteration of daily dosage or frequency of dosing, or route of administration are required.

Patients with Hepatic Impairment

A study which investigated the effect of hepatic impairment on the pharmacokinetics of ondansetron in 24 subjects showed that the plasma clearance of ondansetron is reduced to about 20% of normal, and the serum half-life is significantly prolonged in subjects with severe impairment of hepatic function.

The results in patients with only mildly or moderately impaired hepatic function were less clear. The study showed that in this group the plasma clearance of ondansetron fell to about 50% of that seen in healthy volunteers. Subjects with mild and moderate impairment were not distinguishable from each other for any parameter. This was believed to be partly due to the lack of sensitivity of the Pugh classification system in distinguishing between patients with mild or moderate impairment.

It is recommended that a total daily dose of 8 mg should not be exceeded for patients with moderate or severe hepatic dysfunction. For optimum clinical effect it is recommended that this total daily dose be administered before chemotherapy or radiotherapy.

The severity of the liver disease was assessed according to Pugh's modification of Child's classification (Pugh *et al*, Brit J. Surg. 1973, 60 (8), 646-649). Patients with a Pugh score of 5 or less were considered to have good hepatic function. A patient with a score of 6 was graded as having mild hepatic impairment, 7 to 9 as moderate hepatic impairment and 10 or more as severe hepatic impairment.

The clinical features used in the grading and the weighting system applied are shown in the table below:

Clinical and Biochemical Measurements	Points scored for increasing abnormality		
	1	2	3
Encephalopathy (grade) *	None	1 and 2	3 and 4
Ascites	Absent	Slight	Moderate
Bilirubin ($\mu\text{mol/L}$)	17.1 - 34.2	34.2 - 51.3	>51.3
Albumin (g/L)	35	28 - 35	<28
Prothrombin time (seconds prolonged)	1 - 4	4 - 6	>6
For primary biliary cirrhosis:- Bilirubin ($\mu\text{mol/L}$)	17.1 - 68.4	68.4 - 171	>171

* According to grading of Trey, Burns, and Saunders (1966)

Patients with Poor Sparteine/Debrisoquine Metabolism

There were no significant differences among poor and extensive debrisoquine categorised metabolisers with regard to ondansetron disposition (area under the curve, total systemic clearance, elimination half-life) following a single 8 mg intravenous dose. The effect of repeated dosing was not investigated, nevertheless dosage adjustments will probably not be required in patients receiving ondansetron by either the oral or intravenous route.

4.3 CONTRAINDICATIONS

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

Hypersensitivity to any component of the preparation (see section **4.4 Special warnings and precautions for use**).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Identified precautions

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT₃ receptor antagonists.

Ondansetron prolongs the QT interval in a dose-dependent manner. In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.

Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.

Serotonin syndrome has been described following the concomitant use of ondansetron and other serotonergic drugs (see section **4.5 Interactions with other medicines and other forms of interactions**). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.

As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

Ondansetron orally disintegrating tablets contain aspartame and therefore should be taken with caution in patients with phenylketonuria.

Use in the elderly

No data available.

Paediatric use

Repeat dosing has not been studied in paediatric patients who experience nausea and/or vomiting despite receiving ondansetron prophylaxis or who continue to experience symptoms after ondansetron treatment.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, alfentanil, furosemide, tramadol or propofol.

Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.

Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities (see section **4.4 Special warnings and precautions for use**).

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.

Following a single 8 mg tablet dose of ondansetron, a three to four-fold decrease in the systemic exposure has been seen in adult epileptic subjects maintained on chronic doses of carbamazepine (n = 8) or phenytoin (n = 8) and not receiving chemotherapy. The effect of these enzyme inducing agents on intravenous ondansetron has not been assessed, but the absence of any first pass effects would be expected to result in a smaller change in exposure than seen following oral dosing. Due to the limited efficacy data in subjects on antiepileptics and the many variables that may influence exposure and response, the clinical significance of this drug interaction in cancer patients receiving chemotherapy is not known.

Serotonergic Drugs (e.g., SSRIs and SNRIs)

Serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) has been described following the concomitant use of ondansetron and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) (see section **4.4 Special warnings and precautions for use**).

Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

Oral doses of ondansetron up to 15 mg/kg/day in rats had no effect on male or female fertility.

Use in pregnancy

Category B1

The safety of ondansetron for use in human pregnancy has not been established. Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo, or foetus, the course of gestation and peri- and post-natal development.

However, as animal studies are not always predictive of human response, the use of ondansetron in pregnancy is not recommended.

Use in lactation

Tests have shown that ondansetron is excreted in the breast milk of rats. It is therefore recommended that mothers receiving ondansetron should not breast-feed their babies.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Adverse events are listed below by system organ class and frequency. Frequencies are defined as:

very common ($\geq 1/10$), common ($\geq 1/100$ and $<1/10$), uncommon ($\geq 1/1000$ and $<1/100$), rare ($\geq 1/10,000$ and $<1/1000$) and very rare ($<1/10,000$), including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare and very rare events were generally determined from post-marketing spontaneous data.

The following frequencies are estimated at the standard recommended doses of ondansetron according to indication and formulation. The adverse event profiles in children and adolescents were comparable to that seen in adults.

Immune system disorders

Rare: Immediate hypersensitivity reactions, sometimes severe, including anaphylaxis.

Nervous system disorders

Very common: Headache.

Uncommon: Seizures, movement disorders (including extrapyramidal reactions such as oculogyric crisis, dystonic reactions and dyskinesia have been observed without definitive evidence of persistent clinical sequelae).

Eye disorders

Rare: Transient visual disturbances (e.g. blurred vision) predominantly during i.v. administration.

Very rare: Transient blindness predominantly during i.v. administration. The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.

Cardiac disorders

Uncommon: Arrhythmias, chest pain with or without ST segment depression, bradycardia.

Rare: QTc prolongation (including Torsade de Pointes).

Vascular disorders

Common: Sensation of warmth or flushing.

Uncommon: Hypotension.

Respiratory, thoracic and mediastinal disorders

Uncommon: Hiccups.

Gastrointestinal disorders

Common: Constipation, Xerostomia.

Hepatobiliary disorders

Uncommon: Asymptomatic increases in liver function tests#.

#These events were observed commonly in patients receiving chemotherapy with cisplatin.

Skin and subcutaneous tissue disorders

Very rare: Toxic skin eruption, including toxic epidermal necrolysis.

To date there has been limited safety experience in controlled trials following intramuscular administration.

Of 7,400 patients who have received intravenous ondansetron during clinical trials, 11 experienced major cardiovascular events, including 3 fatalities, which were considered to be drug-related by the investigators (1 probable, 10 possible). It is well known that cardiovascular events, especially of a vascular occlusive nature are not uncommon among patients with cancer, and these events are further increased with cytotoxic chemotherapy, particularly cisplatin.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems> and contact Apotex Medical Information Enquiries/Adverse Drug Reaction Reporting on 1800 195 055.

4.9 OVERDOSE

Symptoms

Little is at present known about overdosage with ondansetron, however, a limited number of patients received overdoses. Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second degree AV block. In all instances, the events resolved completely.

Ondansetron prolongs QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.

Treatment

There is no specific antidote for ondansetron, therefore in cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.

Activated charcoal may reduce absorption of the medicine if given within one or two hours after ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Ondansetron is a potent, highly selective 5HT₃ receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT₃ receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting

induced by cytotoxic chemotherapy and radiotherapy is due to antagonism of 5HT₃ receptors on neurones located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting. In psychomotor testing ondansetron does not impair performance nor cause sedation. Ondansetron does not alter plasma prolactin concentrations.

A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. The clinical relevance of this finding is uncertain.

Clinical trials

Chemotherapy and Radiotherapy Induced Nausea and Vomiting (CINV and RINV)

Adult Studies

Highly Emetogenic Chemotherapy

In a double-blind, randomised study 152 patients were given ondansetron 8 mg i.v. single dose and 173 patients were given 32 mg iv single dose 30 minutes prior to Cisplatin (≥ 50 mg/m²). No significant difference in terms of emesis control or grade of nausea was demonstrated between 8 mg or 32 mg.

However, in some studies conducted in patients receiving medium (50 to 90 mg/m²) or high doses (≥ 100 mg/m²) of cisplatin chemotherapy, the 32 mg single dose has demonstrated a statistically significant superiority over the 8 mg single dose with regard to control of emesis (see section **4.2 Dose and method of administration**).

In a double-blind, randomised, cross-over trial, 103 chemotherapy naive patients scheduled to receive cisplatin (50 to 120 mg/m²) chemotherapy were recruited. Ninety-one patients completed both courses of ondansetron 0.15 mg/kg (8 mg) i.v. x 3 with or without dexamethasone 20 mg i.v. The combination of ondansetron and dexamethasone was shown to be significantly superior to ondansetron alone.

In a randomised, double-blind parallel group study, 420 patients were randomised to receive either ondansetron 16 mg suppository prior to cisplatin chemotherapy (≥ 50 mg/m²) on day 1 followed by ondansetron 16 mg suppository once daily for a further 2 days, or ondansetron 8 mg i.v. prior to cisplatin chemotherapy followed by ondansetron 8 mg orally twice daily for a further 2 days. Results from the primary efficacy analysis (i.e. ≤ 2 emetic episodes on day 1) show that the ondansetron suppository and ondansetron i.v. and oral combined regimens are equivalent. However, results from the secondary efficacy analyses (e.g. number of emetic episodes on Day 1, the worst day of Days 1 to 3 and over all of Days 1 to 3) showed that the ondansetron suppository was less effective. Patients on ondansetron i.v. and oral combined regimen remained free of emesis for significantly longer than patients receiving ondansetron suppository.

In a randomised, double-blind, parallel group study 542 patients were randomised to receive either ondansetron tablets (3 x 8 mg) plus dexamethasone capsules (2 x 6 mg), or i.v. ondansetron 8 mg plus i.v. dexamethasone 20 mg, prior to cisplatin infusion. 24 mg of ondansetron administered orally was as effective as ondansetron 8 mg given i.v. in controlling acute emesis and nausea induced by cisplatin chemotherapy.

Emetogenic Chemotherapy

In a double-blind, parallel group study 82 patients were randomised to either ondansetron 8 mg i.v. prior to cyclophosphamide ($\geq 500 \text{ mg/m}^2$) based chemotherapy (doxorubicin or epirubicin $\geq 40 \text{ mg/m}^2$) followed by 8 mg orally three times a day for 3 to 5 days or metoclopramide 60 mg i.v. prior to chemotherapy followed by 20 mg orally three times a day for 3 to 5 days. Ondansetron was shown to be significantly superior to Metoclopramide.

In a randomised, single-blind study, ondansetron 8 mg orally twice daily in 155 patients was compared with ondansetron 8 mg orally three times daily in 153 patients for 3 to 5 days following chemotherapy. Ondansetron 8 mg i.v. was given prior to cyclophosphamide ($\geq 500 \text{ mg/m}^2$) based chemotherapy (doxorubicin or epirubicin $>40 \text{ mg/m}^2$) on Day 1. Ondansetron 8 mg given orally twice daily was as effective as ondansetron 8 mg given orally three times daily.

In a randomised, double-blind parallel group study, 406 patients were randomised to receive either ondansetron 16 mg suppository once daily for 3 days or ondansetron 8 mg orally twice daily for 3 days.

The first administration of suppository and tablet began 2 hours and 1 to 2 hours respectively prior to cyclophosphamide chemotherapy ($\geq 500 \text{ mg/m}^2$) on day 1. Results from the primary efficacy analysis (≤ 2 emetic episodes on the worst day of days 1 to 3) show that the ondansetron suppository treatment is equivalent to the ondansetron oral treatment. The ondansetron suppository was less effective than ondansetron oral treatment for a number of other secondary efficacy criteria (complete control of emesis on the worst day of Days 1 to 3, total number of emetic episodes Days 1 to 3 and number of emetic episodes on worst day of Days 1 to 3).

Paediatric Studies

Three open-label, uncontrolled, non-comparative studies have been performed with 182 patients, aged 4 to 18 years old with cancer who were given a variety of cisplatin or non-cisplatin regimens. In these trials an initial i.v. dose of ondansetron was followed by oral administration of ondansetron. In these studies, 58% of the 170 evaluable patients had no emetic episodes on Day 1.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Following oral dosing with ondansetron, peak plasma concentrations are achieved in approximately 1.5 hours. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher doses. The absolute bioavailability of the ondansetron tablet is approximately 60% (range 36 to 112%).

Distribution

The plasma protein binding is 70 to 76%. The volume of distribution is 1.8 L/kg.

Metabolism

Ondansetron is extensively metabolised in humans, with approximately 5% of a radiolabelled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by glucuronide or sulphate conjugation. Although some nonconjugated metabolites have pharmaceutical activity, these are not found in plasma concentrations likely to significantly contribute to the biological activity of ondansetron.

Ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes including CYP1A2, CYP2D6 and CYP3A4. This multiplicity of metabolic enzymes capable of metabolising ondansetron means that inhibition or loss of one enzyme (e.g. CYP2D6 genetic deficiency) results in little change in overall rates of ondansetron elimination.

Excretion

The terminal elimination half-life of ondansetron after oral dosing is 4.1 to 11.6 hours. The half-life may be prolonged in the elderly. In patients with severe hepatic impairment, systemic clearance is markedly reduced with prolonged elimination half-lives (15 to 32 h) and an oral bioavailability approaching 100% because of reduced presystemic metabolism.

Paediatrics

In a study of 21 children aged 3-12 years receiving elective surgery with general anaesthesia, the clearance and volume of distribution of ondansetron following a single intravenous dose of 2 mg (3-7 years old) or 4 mg (8-12 years old) were reduced. The size of the change was age-related with clearance falling from about 300 mL/min at 12 years of age to 100 mL/min at 3 years. Volume of distribution fell from about 75 L at 12 years to 17 L at 3 years.

The clinical safety of ondansetron in children under 2 years has not been established. Increased incidence of mortality with no specific target organ toxicity has been observed in young rats with immature drug metabolising enzymes.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Ondansetron did not induce mutations in *Salmonella typhimurium*, *Escherichia coli* or Chinese Hamster Ovary cells in the presence or absence of metabolic activation, and showed no potential for causing chromosomal damage *in vitro* in peripheral human lymphocytes or *in vivo* in a mouse micronucleus assay. No evidence for DNA damage was observed with ondansetron in a yeast mitotic gene conversion assay.

Carcinogenicity

No evidence for carcinogenic activity was found in two year studies at ondansetron doses up to 10 mg/kg/day by gavage in rats or up to 30 mg/kg/day via drinking water in mice.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

- Mannitol
- microcrystalline cellulose
- silicified microcrystalline cellulose
- crospovidone
- aspartame (see section **4.4 Special warnings and precautions for use**)
- colloidal anhydrous silica
- magnesium stearate
- *Art Strawberry FL SD 10761 (BF35)- (Proprietary Ingredient number 111726).*

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine. See section **4.5 Interactions with other medicines and other forms of interactions**.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C

6.5 NATURE AND CONTENTS OF CONTAINER

4 mg Tablets

Blister pack (Aluminium-Aluminium/Peelable blister foil) of 4 or 10 orally disintegrating tablets (APO-ONDANSETRON ODT AUST R 292170)

Blister pack (Aluminium-Aluminium/Peelable blister foil) of 4 or 10 orally disintegrating tablets (APO-ONDANSETRON ODT AUST R 292173)

APO- is a registered trade mark of Apotex Pty Ltd.

Not all strengths and/or pack sizes may be available.


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Ondansetron is a white to off-white powder with a melting point of approximately 230°C. Ondansetron is practically insoluble in water. Solubility decreases with increasing pH from very slightly soluble at pH 3.5 and pH 5.4 to practically insoluble at pH 8. Ondansetron is soluble in chloroform and slightly soluble in acetonitrile and methanol. The pKa of ondansetron as determined by UV monitored partition method is 7.8. The partition coefficient, log P in n-octanol: water is 2.14.

Chemical structure



Chemical name:

(3*RS*)-1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1*H*-imidazol-1-yl)methyl]-4*H*-carbazol-4-one

Molecular Formula: C₁₈H₁₉N₃O

Molecular Weight: 293.4

CAS number

99614-02-5

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

Apotex Pty Ltd

16 Giffnock Avenue

Macquarie Park NSW 2113

Australia

Tel: +61 2 8877 8333

Web: www1.apotex.com/au

9 DATE OF FIRST APPROVAL

24 September 2018

10 DATE OF REVISION

TBD

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information

--	--